PMCPA Case
| Case | AUTH/3545/7/21 |
| Company | Novo Nordisk |
| Complainant | Concerned UK health professional |
| Product / context | Saxenda (liraglutide) patient website |
| Issue | Use of an 0845 business-rate number for side-effect reporting on a patient webpage without written call-cost information |
| Applicable Code | 2021 |
| Complaint received | 22 July 2021 |
| Case completed | 8 September 2021 |
| Breach clauses | Clause 5.1 |
| No breach clauses | Clause 6.1 |
| Sanctions | Undertaking received; additional sanctions not stated |
| Appeal | No appeal |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
One real case. One key lesson. Every week — free.